EP3237452A4 - Protéines de fusion et procédés associés - Google Patents

Protéines de fusion et procédés associés Download PDF

Info

Publication number
EP3237452A4
EP3237452A4 EP15873797.3A EP15873797A EP3237452A4 EP 3237452 A4 EP3237452 A4 EP 3237452A4 EP 15873797 A EP15873797 A EP 15873797A EP 3237452 A4 EP3237452 A4 EP 3237452A4
Authority
EP
European Patent Office
Prior art keywords
methods
fusion proteins
fusion
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP15873797.3A
Other languages
German (de)
English (en)
Other versions
EP3237452A1 (fr
Inventor
Anna Lasorella
Antonio Iavarone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Priority to EP21173909.9A priority Critical patent/EP3925979A3/fr
Priority to EP20197862.4A priority patent/EP3778644A3/fr
Publication of EP3237452A1 publication Critical patent/EP3237452A1/fr
Publication of EP3237452A4 publication Critical patent/EP3237452A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP15873797.3A 2014-12-23 2015-12-23 Protéines de fusion et procédés associés Ceased EP3237452A4 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP21173909.9A EP3925979A3 (fr) 2014-12-23 2015-12-23 Protéines de fusion fgfr-tacc et utilisations associées
EP20197862.4A EP3778644A3 (fr) 2014-12-23 2015-12-23 Protéines de fusion fgfr-tacc et procédés associés

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462096311P 2014-12-23 2014-12-23
PCT/US2015/000270 WO2016105517A1 (fr) 2014-12-23 2015-12-23 Protéines de fusion et procédés associés

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP20197862.4A Division EP3778644A3 (fr) 2014-12-23 2015-12-23 Protéines de fusion fgfr-tacc et procédés associés
EP21173909.9A Division EP3925979A3 (fr) 2014-12-23 2015-12-23 Protéines de fusion fgfr-tacc et utilisations associées

Publications (2)

Publication Number Publication Date
EP3237452A1 EP3237452A1 (fr) 2017-11-01
EP3237452A4 true EP3237452A4 (fr) 2018-12-05

Family

ID=56151260

Family Applications (3)

Application Number Title Priority Date Filing Date
EP20197862.4A Pending EP3778644A3 (fr) 2014-12-23 2015-12-23 Protéines de fusion fgfr-tacc et procédés associés
EP21173909.9A Withdrawn EP3925979A3 (fr) 2014-12-23 2015-12-23 Protéines de fusion fgfr-tacc et utilisations associées
EP15873797.3A Ceased EP3237452A4 (fr) 2014-12-23 2015-12-23 Protéines de fusion et procédés associés

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP20197862.4A Pending EP3778644A3 (fr) 2014-12-23 2015-12-23 Protéines de fusion fgfr-tacc et procédés associés
EP21173909.9A Withdrawn EP3925979A3 (fr) 2014-12-23 2015-12-23 Protéines de fusion fgfr-tacc et utilisations associées

Country Status (2)

Country Link
EP (3) EP3778644A3 (fr)
WO (1) WO2016105517A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150203589A1 (en) 2012-07-24 2015-07-23 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
CA2907152A1 (fr) 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Proteines de fusion et procedes correspondants
US20220098328A1 (en) * 2017-07-27 2022-03-31 Nomocan Pharmaceuticals Llc Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
WO2023230444A2 (fr) * 2022-05-23 2023-11-30 Foundation Medicine, Inc. Fusions abl1 et leurs utilisations
CN118955676A (zh) * 2024-07-26 2024-11-15 珠海丽禾医疗诊断产品有限公司 Cenpa融合抗原及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077165A1 (fr) * 2006-12-22 2008-07-03 Austrian Research Centers Gmbh - Arc Ensemble de marqueurs tumoraux
WO2014018673A2 (fr) * 2012-07-24 2014-01-30 The Trustees Of Columbia University In The City Of New York Protéines de fusion et leurs procédés associés
WO2014130890A1 (fr) * 2013-02-21 2014-08-28 Toma Biosciences, Inc. Procédés, compositions et kits pour l'analyse d'acide nucléique

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
EP0431519B1 (fr) 1989-12-04 1994-06-15 G.D. Searle & Co. Système pour l'administration transdermale d'albutérol
US6683046B1 (en) 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
WO1992015680A1 (fr) 1991-03-06 1992-09-17 Board Of Regents, The University Of Texas System Procedes et compositions d'inhibition selective de l'expression de genes
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
DE69228827T2 (de) 1991-12-18 1999-10-21 Minnesota Mining And Mfg. Co., Saint Paul Mehrschichtige sperrstrukturen
EP0553769B1 (fr) 1992-01-29 1996-01-03 FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG Raquette, en particulier raquette de tennis
RU2174409C2 (ru) 1995-11-30 2001-10-10 Борд оф Риджентс, ЗЭ Юниверсити оф Тексас Систем Способы и композиции для диагностики и лечения рака
US7419661B2 (en) 1997-04-30 2008-09-02 The Centre Of Excellence For Life Sciences Limited Dermal sheath tissue in wound healing
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
EP2314700A1 (fr) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition et méthode destinées à l'attenuation in vivo et in vitro de l'expression génique utilisant de l'ARN double brin
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
CA2386270A1 (fr) 1999-10-15 2001-04-26 University Of Massachusetts Genes de voies d'interference d'arn en tant qu'outils d'interference genetique ciblee
GB9925964D0 (en) 1999-11-03 1999-12-29 Jahoda Colin A B Hair transplantation
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US20020173478A1 (en) 2000-11-14 2002-11-21 The Trustees Of The University Of Pennsylvania Post-transcriptional gene silencing by RNAi in mammalian cells
US7294504B1 (en) 2001-12-27 2007-11-13 Allele Biotechnology & Pharmaceuticals, Inc. Methods and compositions for DNA mediated gene silencing
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
CA2607256A1 (fr) 2005-05-02 2006-11-09 Cold Spring Harbor Laboratory Compositions et procedes destines au diagnostic et au traitement du cancer
BRPI0620408B8 (pt) 2005-12-21 2021-05-25 Novartis Ag derivados de pirimidinil aril uréia sendo inibidores de fgf, seus usos, e preparação farmacêutica
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
AR078411A1 (es) 2009-05-07 2011-11-09 Lilly Co Eli Compuesto de vinil imidazolilo y composicion farmaceutica que lo comprende
EP2945652B1 (fr) * 2013-01-18 2021-07-07 Foundation Medicine, Inc. Méthodes de traitement du cholangiocarcinome
CA2907152A1 (fr) * 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Proteines de fusion et procedes correspondants

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077165A1 (fr) * 2006-12-22 2008-07-03 Austrian Research Centers Gmbh - Arc Ensemble de marqueurs tumoraux
WO2014018673A2 (fr) * 2012-07-24 2014-01-30 The Trustees Of Columbia University In The City Of New York Protéines de fusion et leurs procédés associés
WO2014130890A1 (fr) * 2013-02-21 2014-08-28 Toma Biosciences, Inc. Procédés, compositions et kits pour l'analyse d'acide nucléique

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
A. L. DI STEFANO ET AL: "Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma", CLINICAL CANCER RESEARCH, vol. 21, no. 14, 21 January 2015 (2015-01-21), US, pages 3307 - 3317, XP055482127, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-14-2199 *
ADAM L. COHEN ET AL: "IDH1 and IDH2 Mutations in Gliomas", CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, vol. 13, no. 5, 27 March 2013 (2013-03-27), US, XP055481959, ISSN: 1528-4042, DOI: 10.1007/s11910-013-0345-4 *
BRITTANY C. PARKER ET AL: "The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma", JOURNAL OF CLINICAL INVESTIGATION, 9 January 2013 (2013-01-09), US, XP055481912, ISSN: 0021-9738, DOI: 10.1172/JCI67144 *
GARRETT M FRAMPTON ET AL: "Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing", NATURE BIOTECHNOLOGY, vol. 31, no. 11, 20 October 2013 (2013-10-20), pages 1023 - 1031, XP055511777, ISSN: 1087-0156, DOI: 10.1038/nbt.2696 *
J. S. ROSS ET AL: "New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing", THE ONCOLOGIST, vol. 19, no. 3, 21 February 2014 (2014-02-21), US, pages 235 - 242, XP055308596, ISSN: 1083-7159, DOI: 10.1634/theoncologist.2013-0352 *
JAVLE MILIND ET AL: "Molecular characterization of gallbladder cancer using somatic mutation profiling", HUMAN PATHOLOGY, vol. 45, no. 4, April 2014 (2014-04-01), pages 701 - 708, XP028634812, ISSN: 0046-8177, DOI: 10.1016/J.HUMPATH.2013.11.001 *
NAMEETA SHAH ET AL: "Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data", BMC GENOMICS, BIOMED CENTRAL, vol. 14, no. 818, 22 November 2013 (2013-11-22), pages 1 - 15, XP021167557, ISSN: 1471-2164, DOI: 10.1186/1471-2164-14-818 *
S. ZHENG ET AL: "A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival", GENES AND DEVELOPMENT., vol. 27, no. 13, 24 June 2013 (2013-06-24), US, pages 1462 - 1472, XP055511583, ISSN: 0890-9369, DOI: 10.1101/gad.213686.113 *
See also references of WO2016105517A1 *

Also Published As

Publication number Publication date
EP3925979A2 (fr) 2021-12-22
EP3778644A2 (fr) 2021-02-17
EP3237452A1 (fr) 2017-11-01
WO2016105517A1 (fr) 2016-06-30
EP3778644A3 (fr) 2021-06-02
EP3925979A3 (fr) 2022-03-23

Similar Documents

Publication Publication Date Title
EP3148573A4 (fr) Protéines de fusion ox40l et leurs utilisations
EP3147298A4 (fr) Protéine de fusion pd-l1 et son utilisation
ZA201603262B (en) Interleukin-2 fusion proteins and uses thereof
IL249327A0 (en) mic-1 fusion proteins and their uses
CA3290904A1 (en) Insecticidal proteins and methods for their use
EP3188758A4 (fr) Protéines de fusion sirp alpha-anticorps
EP3229838A4 (fr) Anticorps anti-c10orf54 et leurs utilisations
EP3244727A4 (fr) Protéines insecticides et leurs procédés d'utilisation
EP3215538A4 (fr) Anticorps anti-cd39 et utilisations
EP3122371A4 (fr) Protéines de fusion fgf23
EP3091997A4 (fr) Protéines chimériques de facteur viii et leurs utilisations
EP3142680A4 (fr) Protéine associée à lpa et expression d'arn
IL246355B (en) p97–ids fused proteins
CA3288875A1 (en) Multivalent and multispecific dr5-binding fusion proteins
EP3341021A4 (fr) Anticorps anti-alk et leurs procédés d'utilisation
EP3274457A4 (fr) Protéines de fusion associées à la follistatine et leurs utilisations
EP3225690A4 (fr) Procédé de préparation de protéine de fusion recombinante modifiée par un polysaccharide bactérien et son utilisation
CA3265373A1 (fr) Anticorps anti-acth et leur utilisation
EP3164410B8 (fr) Recuperation de proteine
IL246348B (en) p97 fusion proteins
EP3093296A4 (fr) Oligo-glycosaminoglycane fuc3s4s substitué et son procédé de préparation
SG11201606501PA (en) Nanobody-fluorescent protein fusion
EP3092248A4 (fr) Polypeptides de fusion et leurs méthodes d'utilisation
EP3105254A4 (fr) Protéines hybrides et leurs utilisations
EP3237452A4 (fr) Protéines de fusion et procédés associés

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170616

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101AFI20180612BHEP

Ipc: C12Q 1/6888 20180101ALI20180612BHEP

Ipc: G01N 33/574 20060101ALI20180612BHEP

Ipc: C07K 14/71 20060101ALI20180612BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20181025

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/71 20060101ALI20181020BHEP

Ipc: C12Q 1/6886 20171101ALI20181020BHEP

Ipc: C07K 16/28 20060101AFI20181020BHEP

Ipc: G01N 33/574 20060101ALI20181020BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/574 20060101ALI20181020BHEP

Ipc: C07K 14/71 20060101ALI20181020BHEP

Ipc: C12Q 1/6886 20180101ALI20181020BHEP

Ipc: C07K 16/28 20060101AFI20181020BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/574 20060101ALI20181020BHEP

Ipc: C07K 16/28 20060101AFI20181020BHEP

Ipc: C12Q 1/6886 20180101ALI20181020BHEP

Ipc: C07K 14/71 20060101ALI20181020BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20191004

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20210121